MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

9.39 -0.21

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.37

Максимум

9.46

Ключови измерители

By Trading Economics

Приходи

-491K

-12M

EPS

-0.14

Служители

42

EBITDA

-1.8M

-14M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+202.55% upside

Дивиденти

By Dow Jones

Следващи печалби

8.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

745M

Предишно отваряне

9.6

Предишно затваряне

9.39

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.04.2025 г., 17:01 ч. UTC

Печалби
Значими двигатели на пазара

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25.04.2025 г., 16:10 ч. UTC

Печалби
Значими двигатели на пазара

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26.04.2025 г., 18:14 ч. UTC

Печалби

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

26.04.2025 г., 15:00 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26.04.2025 г., 08:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

25.04.2025 г., 21:24 ч. UTC

Топ новини

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25.04.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

25.04.2025 г., 20:45 ч. UTC

Топ новини

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25.04.2025 г., 20:39 ч. UTC

Печалби

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25.04.2025 г., 20:37 ч. UTC

Топ новини

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25.04.2025 г., 20:19 ч. UTC

Топ новини

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25.04.2025 г., 20:15 ч. UTC

Печалби

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25.04.2025 г., 19:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25.04.2025 г., 19:18 ч. UTC

Пазарно говорене

Oil Futures End Choppy Week With Losses -- Market Talk

25.04.2025 г., 18:47 ч. UTC

Пазарно говорене

Gold Extends Pullback to Close Week -- Market Talk

25.04.2025 г., 18:39 ч. UTC

Топ новини

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25.04.2025 г., 18:34 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25.04.2025 г., 18:32 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

25.04.2025 г., 18:32 ч. UTC

Пазарно говорене
Печалби

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25.04.2025 г., 18:08 ч. UTC

Печалби

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25.04.2025 г., 17:55 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25.04.2025 г., 17:40 ч. UTC

Топ новини

Consumers Continue to Sour on the Economy -- 4th Update

25.04.2025 г., 17:38 ч. UTC

Печалби

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25.04.2025 г., 17:07 ч. UTC

Пазарно говорене

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25.04.2025 г., 16:54 ч. UTC

Пазарно говорене
Печалби

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25.04.2025 г., 16:46 ч. UTC

Печалби

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25.04.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

25.04.2025 г., 16:12 ч. UTC

Топ новини

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25.04.2025 г., 16:03 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25.04.2025 г., 15:52 ч. UTC

Пазарно говорене

Grains Mixed on Low Volume Trade -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

202.55% нагоре

12-месечна прогноза

Среден 28.5 USD  202.55%

Висок 42 USD

Нисък 15 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

9.26 / 9.45Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Very Strong Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.